Improved precision of exposure–response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment
暂无分享,去创建一个
[1] Frank Bretz,et al. Model‐based dose finding under model uncertainty using general parametric models , 2013, Statistics in medicine.
[2] Frank Bretz,et al. Dose Finding – A Challenge in Statistics , 2008, Biometrical journal. Biometrische Zeitschrift.
[3] M. Mintun,et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.
[4] Holger Dette,et al. Optimal Designs for Estimating the Interesting Part of a Dose-Effect Curve , 2007, Journal of biopharmaceutical statistics.
[5] Mark Slifstein,et al. Measuring Drug Occupancy in the Absence of a Reference Region: The Lassen Plot Re-Visited , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[6] J. S. Duncan,et al. Benzodiazepine Receptor Quantification in vivo in Humans Using [11C]Flumazenil and PET: Application of the Steady-State Principle , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[7] R. P. Maguire,et al. Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[8] M. Karlsson,et al. Optimizing disease progression study designs for drug effect discrimination , 2013, Journal of Pharmacokinetics and Pharmacodynamics.
[9] W. Näther. Optimum experimental designs , 1994 .
[10] G. Sedvall,et al. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. , 1986, Science.
[11] L. Sheiner,et al. Understanding the Dose-Effect Relationship , 1981, Clinical pharmacokinetics.
[12] Jack A. Cook,et al. The Use of Clinical Trial Simulation to Support Dose Selection: Application to Development of a New Treatment for Chronic Neuropathic Pain , 2003, Pharmaceutical Research.
[13] Andrew C. Hooker,et al. A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 — Estimating occupancy in the absence of a reference region , 2013, NeuroImage.
[14] M. Foracchia,et al. POPED, a software for optimal experiment design in population kinetics , 2004, Comput. Methods Programs Biomed..
[15] Andrew C. Hooker,et al. Robust Population Pharmacokinetic Experiment Design , 2005, Journal of Pharmacokinetics and Pharmacodynamics.
[16] Holger Dette,et al. Optimal Designs for Dose-Finding Studies , 2008 .
[17] Andrew C. Hooker,et al. PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool , 2012, Comput. Methods Programs Biomed..
[18] E. Whalen,et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens , 2005, Pain.
[19] G. Sedvall,et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.